Cullinan Therapeutics, Inc. SEC filings CGEM
Cullinan Therapeutics, Inc. has 466 filings in SEC EDGAR's recent list, going back to Nov 2, 2020. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 144 | Notice of proposed sale | Nov 5, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 2, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 24, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 14, 2026 | Sep 13, 2026 |
| 4 | Insider transaction | Sep 10, 2026 | Sep 8, 2026 |
| 144 | Notice of proposed sale | Sep 8, 2026 | — |
| 4 | Insider transaction | Aug 14, 2026 | Aug 13, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 14, 2026 | — |
| 144 | Notice of proposed sale | Aug 13, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 13, 2026 | Aug 12, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 7, 2026 | — |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 4 | Insider transaction | Jul 7, 2026 | Jul 6, 2026 |
| 144 | Notice of proposed sale | Jul 6, 2026 | — |
| 4 | Insider transaction | Jul 2, 2026 | Jun 30, 2026 |
| 4 | Insider transaction | Jul 2, 2026 | Jun 30, 2026 |
| 4 | Insider transaction | Jun 18, 2026 | Jun 16, 2026 |
| 4 | Insider transaction | Jun 18, 2026 | Jun 16, 2026 |
| 4 | Insider transaction | Jun 18, 2026 | Jun 16, 2026 |
| 4 | Insider transaction | Jun 18, 2026 | Jun 16, 2026 |
| 4 | Insider transaction | Jun 18, 2026 | Jun 16, 2026 |
| 4 | Insider transaction | Jun 18, 2026 | Jun 16, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 16, 2026 | Jun 16, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 10, 2026 | Jun 10, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 8, 2026 | Jun 6, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 18, 2026 | May 18, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2026 | — |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
| 4 | Insider transaction | May 6, 2026 | May 5, 2026 |
| 144 | Notice of proposed sale | May 5, 2026 | — |
| S-3ASR | Automatic shelf registration | Apr 28, 2026 | — |
| DEFA14A | Additional proxy material | Apr 28, 2026 | — |
| DEF 14A | Proxy statement | Apr 28, 2026 | Apr 27, 2026 |
| ARS | Annual report to shareholders | Apr 28, 2026 | Dec 31, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Mar 26, 2026 | — |
| S-8 | Employee stock plan registration | Mar 10, 2026 | — |
| 10-K | Annual report | Mar 10, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 10, 2026 | Mar 10, 2026 |
| 4 | Insider transaction | Mar 9, 2026 | Mar 5, 2026 |
| 144 | Notice of proposed sale | Mar 5, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Mar 4, 2026 | — |
| 4 | Insider transaction | Feb 26, 2026 | Feb 25, 2026 |
| 4 | Insider transaction | Feb 25, 2026 | Feb 23, 2026 |
| 4 | Insider transaction | Feb 25, 2026 | Feb 24, 2026 |
| 4 | Insider transaction | Feb 25, 2026 | Feb 24, 2026 |
| 4 | Insider transaction | Feb 25, 2026 | Feb 24, 2026 |
| 144 | Notice of proposed sale | Feb 25, 2026 | — |
| 4 | Insider transaction | Feb 23, 2026 | Feb 20, 2026 |
| 4 | Insider transaction | Feb 23, 2026 | Feb 20, 2026 |
| 4 | Insider transaction | Feb 23, 2026 | Feb 20, 2026 |
| 4 | Insider transaction | Feb 23, 2026 | Feb 20, 2026 |
| 4 | Insider transaction | Feb 23, 2026 | Feb 20, 2026 |
| 144 | Notice of proposed sale | Feb 23, 2026 | — |
| 144 | Notice of proposed sale | Feb 20, 2026 | — |
| 4 | Insider transaction | Feb 19, 2026 | Feb 18, 2026 |
| 4 | Insider transaction | Feb 19, 2026 | Feb 18, 2026 |
| 4 | Insider transaction | Feb 19, 2026 | Feb 18, 2026 |
| 4 | Insider transaction | Feb 19, 2026 | Feb 18, 2026 |
| 4 | Insider transaction | Feb 19, 2026 | Feb 18, 2026 |
| 4 | Insider transaction | Feb 19, 2026 | Feb 18, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| 4 | Insider transaction | Feb 13, 2026 | Feb 12, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Jan 30, 2026 | — |
| 4 | Insider transaction | Jan 23, 2026 | Jan 22, 2026 |
| 144 | Notice of proposed sale | Jan 22, 2026 | — |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Jan 8, 2026 | Jan 8, 2026 |
| 4 | Insider transaction | Jan 5, 2026 | Dec 31, 2025 |
| 4 | Insider transaction | Dec 29, 2025 | Dec 23, 2025 |
| 4 | Insider transaction | Dec 22, 2025 | Dec 19, 2025 |
| 4 | Insider transaction | Dec 19, 2025 | Dec 18, 2025 |
| 4 | Insider transaction | Dec 19, 2025 | Dec 18, 2025 |
| 4 | Insider transaction | Dec 19, 2025 | Dec 18, 2025 |
| 144 | Notice of proposed sale | Dec 19, 2025 | — |
| 4 | Insider transaction | Dec 16, 2025 | Dec 12, 2025 |
| 144 | Notice of proposed sale | Dec 15, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 8, 2025 | Dec 8, 2025 |
| 4 | Insider transaction | Nov 25, 2025 | Nov 24, 2025 |
| 144 | Notice of proposed sale | Nov 24, 2025 | — |
| 8-K |
Current report
Agreement ended
|
Nov 21, 2025 | Nov 18, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Nov 14, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Nov 14, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Nov 13, 2025 | — |
| 10-Q | Quarterly report | Nov 6, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations, Other events
|
Nov 6, 2025 | Nov 6, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 3, 2025 | Nov 3, 2025 |
| 4 | Insider transaction | Oct 30, 2025 | Oct 28, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Oct 30, 2025 | — |
| 4 | Insider transaction | Oct 21, 2025 | Oct 14, 2025 |
| 4 | Insider transaction | Oct 10, 2025 | Oct 8, 2025 |
| 3 | Initial insider ownership | Oct 10, 2025 | Oct 8, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Oct 10, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 4, 2025 | Sep 4, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 14, 2025 | — |
| 4 | Insider transaction | Aug 8, 2025 | Aug 7, 2025 |
| 4 | Insider transaction | Aug 8, 2025 | Aug 7, 2025 |
| 3 | Initial insider ownership | Aug 8, 2025 | Aug 7, 2025 |
| 3 | Initial insider ownership | Aug 8, 2025 | Aug 7, 2025 |
| 10-Q | Quarterly report | Aug 7, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Aug 7, 2025 | Aug 7, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 6, 2025 | — |
| 4 | Insider transaction | Jun 16, 2025 | Jun 12, 2025 |
| 4 | Insider transaction | Jun 16, 2025 | Jun 12, 2025 |
| 4 | Insider transaction | Jun 16, 2025 | Jun 12, 2025 |
| 4 | Insider transaction | Jun 16, 2025 | Jun 12, 2025 |
| 4 | Insider transaction | Jun 16, 2025 | Jun 12, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2025 | Jun 12, 2025 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jun 4, 2025 | Jun 4, 2025 |
| 10-Q | Quarterly report | May 8, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 8, 2025 | May 8, 2025 |
| ARS | Annual report to shareholders | Apr 25, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 25, 2025 | — |
| DEF 14A | Proxy statement | Apr 25, 2025 | Apr 24, 2025 |
| 4 | Insider transaction | Feb 27, 2025 | Feb 25, 2025 |
| 4 | Insider transaction | Feb 27, 2025 | Feb 25, 2025 |
| 4 | Insider transaction | Feb 27, 2025 | Feb 25, 2025 |
| 4 | Insider transaction | Feb 27, 2025 | Feb 25, 2025 |
| S-8 | Employee stock plan registration | Feb 27, 2025 | — |
| 10-K | Annual report | Feb 27, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Feb 27, 2025 | Feb 27, 2025 |
| 4 | Insider transaction | Feb 21, 2025 | Feb 19, 2025 |
| 4 | Insider transaction | Feb 21, 2025 | Feb 19, 2025 |
| 4 | Insider transaction | Feb 21, 2025 | Feb 19, 2025 |
| 4 | Insider transaction | Feb 21, 2025 | Feb 19, 2025 |
| 4 | Insider transaction | Feb 21, 2025 | Feb 19, 2025 |
| 4 | Insider transaction | Feb 21, 2025 | Feb 19, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jan 29, 2025 | Jan 28, 2025 |
| 4 | Insider transaction | Jan 7, 2025 | Jan 6, 2025 |
| 144 | Notice of proposed sale | Jan 6, 2025 | — |
| 4 | Insider transaction | Dec 27, 2024 | Dec 24, 2024 |
| 4 | Insider transaction | Dec 20, 2024 | Dec 18, 2024 |
| 4 | Insider transaction | Dec 20, 2024 | Dec 18, 2024 |
| 4 | Insider transaction | Dec 20, 2024 | Dec 18, 2024 |
| 4 | Insider transaction | Dec 16, 2024 | Dec 12, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 12, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Nov 8, 2024 | — |
| 4 | Insider transaction | Nov 7, 2024 | Nov 5, 2024 |
| 10-Q | Quarterly report | Nov 7, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 7, 2024 | Nov 7, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 4, 2024 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Oct 31, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Oct 22, 2024 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 16, 2024 | Oct 16, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 17, 2024 | Sep 17, 2024 |
| 4 | Insider transaction | Sep 9, 2024 | Sep 5, 2024 |
| 144 | Notice of proposed sale | Sep 5, 2024 | — |
| 3 | Initial insider ownership | Aug 9, 2024 | Aug 8, 2024 |
| 4 | Insider transaction | Aug 9, 2024 | Aug 8, 2024 |
| 10-Q | Quarterly report | Aug 8, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2024 | Aug 8, 2024 |
| 4 | Insider transaction | Jul 9, 2024 | Jul 5, 2024 |
| 144 | Notice of proposed sale | Jul 5, 2024 | — |
| 4 | Insider transaction | Jul 2, 2024 | Jul 1, 2024 |
| 4 | Insider transaction | Jun 27, 2024 | Jun 26, 2024 |
| 4 | Insider transaction | Jun 27, 2024 | Jun 26, 2024 |
| 4 | Insider transaction | Jun 27, 2024 | Jun 26, 2024 |
| 4 | Insider transaction | Jun 27, 2024 | Jun 26, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 27, 2024 | Jun 26, 2024 |
| 4 | Insider transaction | Jun 11, 2024 | Jun 10, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Jun 7, 2024 | — |
| EFFECT | Filing | Jun 4, 2024 | — |
| 424B3 | Prospectus | Jun 4, 2024 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 3, 2024 | Jun 1, 2024 |
| CORRESP | Letter to the SEC | May 31, 2024 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 23, 2024 | May 23, 2024 |
| 4 | Insider transaction | May 23, 2024 | May 23, 2024 |
| UPLOAD | Letter from the SEC | May 20, 2024 | — |
| 4 | Insider transaction | May 16, 2024 | May 15, 2024 |
| 3 | Initial insider ownership | May 16, 2024 | May 15, 2024 |
| S-3 | Shelf registration | May 16, 2024 | — |
| ARS | Annual report to shareholders | May 16, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | May 16, 2024 | — |
| DEF 14A | Proxy statement | May 16, 2024 | Jun 26, 2024 |
| 10-Q | Quarterly report | May 15, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations, Officer or director change
|
May 15, 2024 | May 9, 2024 |
| 4 | Insider transaction | May 8, 2024 | May 6, 2024 |
| 144 | Notice of proposed sale | May 6, 2024 | — |
| 4 | Insider transaction | Apr 30, 2024 | Apr 29, 2024 |
| 3 | Initial insider ownership | Apr 30, 2024 | Apr 29, 2024 |
| 8-K |
Current report
Officer or director change
|
Apr 29, 2024 | Apr 29, 2024 |
| SC 13G | Ownership over 5% (passive) | Apr 24, 2024 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Bylaw or fiscal year change, Regulation FD disclosure, Other events
|
Apr 16, 2024 | Apr 15, 2024 |
| 3 | Initial insider ownership | Apr 2, 2024 | Mar 29, 2024 |
| S-8 | Employee stock plan registration | Mar 14, 2024 | — |
| 10-K | Annual report | Mar 14, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 14, 2024 | Mar 14, 2024 |
| 4 | Insider transaction | Feb 23, 2024 | Feb 22, 2024 |
| 4 | Insider transaction | Feb 23, 2024 | Feb 22, 2024 |
| 4 | Insider transaction | Feb 23, 2024 | Feb 22, 2024 |
| 4 | Insider transaction | Feb 23, 2024 | Feb 22, 2024 |
| 4 | Insider transaction | Feb 23, 2024 | Feb 22, 2024 |
| 4 | Insider transaction | Feb 23, 2024 | Feb 22, 2024 |
| SC 13G | Ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2024 | — |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CGEM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1789972
- Former names
- Cullinan Oncology, Inc. (until Apr 2, 2024); Cullinan Management, Inc. (until Feb 22, 2021); Cullinan Oncology, LLC (until Jan 6, 2021)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.